Stereotactic body radiotherapy for oligometastases

The Lancet Oncology

Volumn 14, Issue 1, 2013, Pages

  Tree, Alison C ^a   Khoo, Vincent S ^a,b   Eeles, Rosalind A ^a   Ahmed, Merina ^a   Dearnaley, David P ^b   Hawkins, Maria A ^a   Huddart, Robert A ^b   Nutting, Christopher M ^a   Ostler, Peter J ^c   van As, Nicholas J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; CANCER CONTROL; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DISEASE FREE SURVIVAL; DISTANT METASTASIS; HUMAN; IMAGE GUIDED RADIOTHERAPY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS; METASTASIS NUMBER; METASTASIS RESECTION; OLIGOMETASTASIS; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION INJURY; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; TUMOR VOLUME;

DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; NEOPLASM METASTASIS; RADIOSURGERY; RADIOTHERAPY, IMAGE-GUIDED;

EID: 84871828017     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70510-7     Document Type: Review

References (87)

1. Halsted WS I. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 1907, 46:1-19.
2. Hellman S Karnofsky Memorial Lecture. Natural history of small breast cancers. J Clin Oncol 1994, 12:2229-2234.
3. Fisher B Laboratory and clinical research in breast cancer-a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res 1980, 40:3863-3874.
4. Hellman S, Weichselbaum RR Importance of local control in an era of systemic therapy. Nat Clin Pract Oncol 2005, 2:60-61.
5. Hellman S, Weichselbaum RR Oligometastases. J Clin Oncol 1995, 13:8-10.
6. Gupta GP, Massague J Cancer metastasis: building a framework. Cell 2006, 127:679-695.
7. Liu W, Laitinen S, Khan S, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009, 15:559-565.
8. Navin N, Kendall J, Troge J, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011, 472:90-94.
9. Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011, 144:27-40.
10. Miller G, Biernacki P, Kemeny NE, et al. Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg 2007, 205:231-238.
11. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230:309-318. discussion 318-21.
12. Casiraghi M, De Pas T, Maisonneuve P, et al. A 10-year single-center experience on 708 lung metastasectomies: the evidence of the international registry of lung metastases. J Thorac Oncol 2011, 6:1373-1378.
13. Christodouleas JP, Marks LB Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses: in regard to Milano et al. (Int J Radiat Oncol Biol Phys 2009;73:832-837). Int J Radiat Oncol Biol Phys 2009, 74:1628. author reply 1628-29.
14. Niibe Y, Hayakawa K Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol 2010, 40:107-111.
15. Withers HR, Lee SP Modeling growth kinetics and statistical distribution of oligometastases. Semin Radiat Oncol 2006, 16:111-119.
16. Rubin P, Green J Solitary metastases 1968, Charles C Thomas, Springfield, IL.
17. Rubin P, Brasacchio R, Katz A Solitary metastases: illusion versus reality. Semin Radiat Oncol 2006, 16:120-130.
18. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006, 94:982-999.
19. Primrose JN Surgery for colorectal liver metastases. Br J Cancer 2010, 102:1313-1318.
20. van Geel AN, Rm van Der Sijp J, Schmitz PI Which soft tissue sarcoma patients with lung metastases should not undergo pulmonary resection?. Sarcoma 2002, 6:57-60.
21. Kaifi JT, Gusani NJ, Deshaies I, et al. Indications and approach to surgical resection of lung metastases. J Surg Oncol 2010, 102:187-195.
22. Pawlik TM, Choti MA Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 2007, 11:1057-1077.
23. Sardenberg RA, Figueiredo LP, Haddad FJ, Gross JL, Younes RN Pulmonary metastasectomy from soft tissue sarcomas. Clinics (Sao Paulo) 2010, 65:871-876.
24. Meimarakis G, Angele M, Staehler M, et al. Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases. Am J Surg 2011, 202:158-167.
25. García Franco CE, Torre W, Tamura A, et al. Long-term results after resection for bone sarcoma pulmonary metastases. Eur J Cardiothorac Surg 2010, 37:1205-1208.
26. Watanabe K, Nagai K, Kobayashi A, Sugito M, Saito N Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer. Br J Surg 2009, 96:1058-1065.
27. Rashid OM, Takabe K The evolution of the role of surgery in the management of breast cancer lung metastasis. J Thorac Dis 2012, 4:420-424.
28. Potters L, Kavanagh B, Galvin JM, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010, 76:326-332.
29. Timmerman RD, Kavanagh BD Stereotactic body radiation therapy. Curr Probl Cancer 2005, 29:120-157.
30. Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 2007, 25:947-952.
31. Lartigau E Stereotactic body radiotherapy. BMJ 2011, 343:d4286.
32. Milano MT, Katz AW, Zhang H, Okunieff P Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 2012, 83:878-886.
33. Lo SS, Moffatt-Bruce SD, Dawson LA, et al. The role of local therapy in the management of lung and liver oligometastases. Nat Rev Clin Oncol 2011, 8:405-416.
34. Høyer M, Swaminath A, Bydder S, et al. Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys 2012, 82:1047-1057.
35. Schefter TE, Kavanagh BD Radiation therapy for liver metastases. Semin Radiat Oncol 2011, 21:264-270.
36. Dhakal S, Corbin KS, Milano MT, et al. Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival. Int J Radiat Oncol Biol Phys 2012, 82:940-945.
37. Ricardi U, Filippi AR, Guarneri A, et al. Stereotactic body radiation therapy for lung metastases. Lung Cancer 2012, 75:77-81.
38. Zhang Y, Xiao JP, Zhang HZ, et al. Stereotactic body radiation therapy favors long-term overall survival in patients with lung metastases: five-year experience of a single-institution. Chin Med J (Engl) 2011, 124:4132-4137.
39. Vautravers-Dewas C, Dewas S, Bonodeau F, et al. Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship?. Int J Radiat Oncol Biol Phys 2011, 81:e39-e47.
40. Carey Sampson M, Katz A, Constine LS Stereotactic body radiation therapy for extracranial oligometastases: does the sword have a double edge?. Semin Radiat Oncol 2006, 16:67-76.
41. Timmerman RD An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol 2008, 18:215-222.
42. Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 2010, 37:4078-4101.
43. Bignardi M, Navarria P, Mancosu P, et al. Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases. Int J Radiat Oncol Biol Phys 2011, 81:831-838.
44. Casamassima F, Masi L, Menichelli C, et al. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori 2011, 97:49-55.
45. Choi CW, Cho CK, Yoo SY, et al. Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer. Int J Radiat Oncol Biol Phys 2009, 74:147-153.
46. Kim MS, Yoo SY, Cho CK, et al. Stereotactic body radiotherapy for isolated para-aortic lymph node recurrence after curative resection in gastric cancer. J Korean Med Sci 2009, 24:488-492.
47. Kim MS, Choi C, Yoo S, et al. Stereotactic body radiation therapy in patients with pelvic recurrence from rectal carcinoma. Jpn J Clin Oncol 2008, 38:695-700.
48. Casamassima F, Livi L, Masciullo S, et al. Stereotactic radiotherapy for adrenal gland metastases: University of Florence experience. Int J Radiat Oncol Biol Phys 2012, 82:919-923.
49. Chawla S, Chen Y, Katz AW, et al. Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys 2009, 75:71-75.
50. Holy R, Piroth M, Pinkawa M, Eble MJ Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol 2011, 187:245-251.
51. Scorsetti M, Alongi F, Filippi AR, et al. Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients. Acta Oncol 2012, 51:618-623.
52. Torok J, Wegner RE, Burton SA, Heron DE Stereotactic body radiation therapy for adrenal metastases: a retrospective review of a noninvasive therapeutic strategy. Future Oncol 2010, 7:145-151.
53. Milano MT, Katz AW, Muhs AG, et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 2008, 112:650-658.
54. Milano MT, Katz AW, Schell MC, Philip A, Okunieff P Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2008, 72:1516-1522.
55. Salama JK, Hasselle MD, Chmura SJ, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 2011, 118:2962-2970.
56. Kang JK, Kim MS, Kim JH, et al. Oligometastases confined one organ from colorectal cancer treated by SBRT. Clin Exp Metastasis 2010, 27:273-278.
57. Inoue T, Katoh N, Aoyama H, et al. Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions. Jpn J Clin Oncol 2010, 40:788-794.
58. Stinauer MA, Kavanagh BD, Schefter TE, et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol 2011, 6:34.
59. Bae SH, Kim MS, Cho CK, et al. High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases. J Surg Oncol 2012, 106:138-143.
60. Jereczek-Fossa BA, Beltramo G, Fariselli L, et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82:889-897.
61. Hoyer M, Roed H, Traberg Hansen A, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 2006, 45:823-830.
62. Wersäll PJ, Blomgren H, Lax I, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol 2005, 77:88-95.
63. Svedman C, Sandström P, Pisa P, et al. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol 2006, 45:870-875.
64. Nuyttens JJ, Prevost JB, Van der Voort van Zijp NC, Hoogeman M, Levendag PC Curative stereotactic robotic radiotherapy treatment for extracranial, extrapulmonary, extrahepatic, and extraspinal tumors: technique, early results, and toxicity. Technol Cancer Res Treat 2007, 6:605-610.
65. Greco C, Zelefsky MJ, Lovelock M, et al. Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. Int J Radiat Oncol Biol Phys 2011, 79:1151-1157.
66. Okunieff P, Petersen AL, Philip A, et al. Stereotactic body radiation therapy (SBRT) for lung metastases. Acta Oncol 2006, 45:808-817.
67. Muacevic A, Kufeld M, Rist C, Wowra B, Stief C, Staehler M Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. Urol Oncol 2011, published online April 13. http://dx.doi.org/10.1016/j.urolonc.2011.02.023.
68. Wang XS, Rhines LD, Shiu AS, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol 2012, 13:395-402.
69. Yamada Y, Bilsky MH, Lovelock DM, et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys 2008, 71:484-490.
70. Gerszten PC, Burton SA, Ozhasoglu C, Welch WC Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine (Phila Pa 1976) 2007, 32:193-199.
71. Zelefsky MJ, Greco C, Motzer R, et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 2011, 82:1744-1778.
72. Nguyen QN, Shiu AS, Rhines LD, et al. Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010, 76:1185-1192.
73. Martin A, Gaya A Stereotactic body radiotherapy: a review. Clin Oncol (R Coll Radiol) 2010, 22:157-172.
74. Gibbs IC, Patil C, Gerszten PC, Adler JR, Burton SA Delayed radiation-induced myelopathy after spinal radiosurgery. Neurosurgery 2009, 64(2 suppl):A67-A72.
75. Chang UK, Youn SM, Park SQ, Rhee CH Clinical results of cyberknife(r) radiosurgery for spinal metastases. J Korean Neurosurg Soc 2009, 46:538-544.
76. Boehling NS, Grosshans DR, Allen PK, et al. Vertebral compression fracture risk after stereotactic body radiotherapy for spinal metastases. J Neurosurg Spine 2012, 16:379-386.
77. Cunha MV, Al-Omair A, Atenafu EG, et al. Vertebral compression fracture (VCF) after spine stereotactic body radiation therapy (SBRT): analysis of predictive factors. Int J Radiat Oncol Biol Phys 2012, 84:e343-e349.
78. Khan AJ, Mehta PS, Zusag TW, et al. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother Oncol 2006, 81:163-167.
79. Milano MT, Katz AW, Okunieff P Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ. Am J Clin Oncol 2010, 33:157-163.
80. Takeda A, Kunieda E, Ohashi T, Aoki Y, Koike N, Takeda T Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol 2011, 101:255-259.
81. Scorsetti M, Mancosu P, Navarria P, et al. Stereotactic body radiation therapy (SBRT) for adrenal metastases: a feasibility study of advanced techniques with modulated photons and protons. Strahlenther Onkol 2011, 187:238-244.
82. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009, 27:1572-1578.
83. Wang JZ, Huang Z, Lo SS, Yuh WT, Mayr NA A generalized linear-quadratic model for radiosurgery, stereotactic body radiation therapy, and high-dose rate brachytherapy. Sci Transl Med 2010, 2:39ra48.
84. Park C, Papiez L, Zhang S, Story M, Timmerman RD Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70:847-852.
85. Hasselle MD, Haraf DJ, Rusthoven KE, et al. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol 2012, 7:376-381.
86. McCammon R, Schefter TE, Gaspar LE, Zaemisch R, Gravdahl D, Kavanagh B Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2009, 73:112-118.
87. Foote M, Letourneau D, Hyde D, et al. Technique for stereotactic body radiotherapy for spinal metastases. J Clin Neurosci 2011, 18:276-279.